Ultragenyx Receives FDA Priority Review for DTX401 Gene Therapy for GSD Type Ia
Feb 23, 2026
The FDA has accepted Ultragenyx's BLA for DTX401, an AAV gene therapy for Glycogen Storage Disease Type Ia, granting Priority Review with a PDUFA action date of August 23, 2026.